In the initial phases of MASLD, LSECs demonstrate a downregulation of pro-inflammatory chemokines via a mitogen-activated protein kinase (MAPK)-dependent pathway, including CCL2, potentially serving as a compensatory mechanism to impede disease progression (28). Here, CCL2 is linked to metabolic dysfunction-associated steatotic liver disease.